COMMUNIQUÉ DE PRESSE

par Polyphor AG (isin : CH0106213793)

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Spexis AG / Key word(s): Strategic Company Decision
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

30-Jun-2023 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Ad hoc announcement pursuant to Art. 53 LR

Allschwil, Switzerland, June 30, 2023

 

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities. Spexis continues to seek additional funding, a strategic transaction or both to advance its ColiFin® Phase 3 program through the planned single pivotal efficacy and safety COPA study following the completion of the COPILOT once-a-day dosing, safety and tolerability clinical trial.

Maxim Group LLC is a full-service investment banking firm headquartered in New York with approximately 240 employees. Maxim Group provides a full array of financial services, including investment banking; private wealth management; and global institutional equity, fixed-income, and derivatives sales and trading, as well as equity research.

Commenting on the engagement of Maxim Group by Spexis, Jeff Wager, MD, Chair & CEO, remarked, “The engagement of Maxim Group to assist us in our M & A and fundraising efforts is aligned with our mission to fully leverage the recently announced relationship with SPRIM Global Investments and strategic opportunities within the current biotech markets to fully finance our lead asset – the ColiFin® Phase 3 program.”

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.

 

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information please contact:

For Investors: 
 
Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com
For Media:
 
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch
 

 

 



End of Inside Information
Language:English
Company:Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone:+41 61 567 1600
Fax:+41 61 567 1601
E-mail:info@spexisbio.com
Internet:www.spexisbio.com
ISIN:CH0106213793
Valor:SPEX
Listed:SIX Swiss Exchange
EQS News ID:1669425

 
End of AnnouncementEQS News Service

1669425  30-Jun-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1669425&application_name=news&site_id=symex
Voir toutes les actualités de Polyphor AG